關(guān)鍵詞

CAR-T細(xì)胞?達(dá)雷妥尤單抗 2型糖尿病 登革熱疫苗 耐藥性?脊髓灰質(zhì)炎病毒疫苗 依拉環(huán)素 CAR-T 度普利尤單抗

?

#今日行業(yè)熱點(diǎn)#

①The Lancet：CAR T-cell therapy in autoimmune diseases

綜述：CAR-T細(xì)胞靶向自身反應(yīng)性B細(xì)胞的研究進(jìn)展

DOI: 10.1016/S0140-6736(23)01126-1

②The Lancet Haematology：Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

臨床試驗(yàn)：達(dá)雷妥尤單抗聯(lián)合卡非佐米、來那度胺、地塞米松（Dara-KRd）用于新診斷多發(fā)性骨髓瘤患者的MASTER試驗(yàn)的最終分析結(jié)果

DOI: 10.1016/S2352-3026(23)00236-3

③The Lancet Diabetes and Endocrinology：Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)

臨床研究：減重誘導(dǎo)2型糖尿病前期患者緩解的機(jī)制：一項(xiàng)隨機(jī)、對(duì)照、多中心糖尿病前期生活方式干預(yù)研究(PLIS)的事后分析

DOI: 10.1016/S2213-8587(23)00235-8

④The Lancet Infectious Diseases：Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial

TV005四價(jià)登革熱疫苗在登革熱流行血清型和年齡組的安全性和持久免疫原性：一項(xiàng)隨機(jī)對(duì)照試驗(yàn)

DOI: 10.1016/S1473-3099(23)00520-0

⑤The Lancet Infectious Diseases：Effectiveness of long-lasting insecticidal nets with pyriproxyfen–pyrethroid, chlorfenapyr–pyrethroid, or piperonyl butoxide–pyrethroid versus pyrethroid only against malaria in Tanzania: final-year results of a four-arm, single-blind, cluster-randomised trial

撒哈拉以南非洲殺蟲劑混合物對(duì)擬除蟲菊酯耐藥性的有效性和耐久性：一項(xiàng)四臂、單盲、集群隨機(jī)試驗(yàn)的最后一年結(jié)果

DOI: 10.1016/S1473-3099(23)00420-6

⑥The Lancet Microbe：Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial

單劑滅活脊髓灰質(zhì)炎病毒疫苗后免疫力的持續(xù)性：一項(xiàng)Ⅳ期、開放標(biāo)簽、非隨機(jī)臨床試驗(yàn)

DOI: 10.1016/S2666-5247(23)00215-X

⑦全球首個(gè)氟環(huán)素類抗菌藥物依拉環(huán)素用于復(fù)雜性腹腔內(nèi)感染（cIAI）的新藥上市許可申請(qǐng)（NDA）在中國(guó)臺(tái)灣獲批上市

⑧靶向Nectin-4 ADC創(chuàng)新藥9MW2821與PD-1抑制劑聯(lián)合用于局部晚期或轉(zhuǎn)移性尿路上皮癌的Ib/II期臨床試驗(yàn)完成首例患者給藥

⑨IL-4/IL-13抑制劑度普利尤單抗（Dupixent）的補(bǔ)充生物制劑許可申請(qǐng)（sBLA）獲FDA授予優(yōu)先審評(píng)資格，用于1至11歲嗜酸性粒細(xì)胞性食管炎（EoE）

⑩BCMA/CD19雙靶點(diǎn)自體CAR-T候選產(chǎn)品GC012F針對(duì)高危多發(fā)性骨髓瘤新確診患者的最新臨床數(shù)據(jù)積極，嚴(yán)格完全緩解率高達(dá)100%

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！